Updated:
Neurocrine Biosciences
Neurocrine develops and commercializes medicines for neuroscience and related disorders; it completed the Soleno acquisition in May 2026.
Overview
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders. Its business combines marketed medicines with a research and development pipeline. On May 18, 2026, Neurocrine completed its acquisition of Soleno Therapeutics, which became a wholly owned subsidiary. For fiscal 2025, ended December 31, 2025, it reported revenue of approximately $2.860 billion and total assets of approximately $4.632 billion at year-end.
Company overview
- Legal name
- NEUROCRINE BIOSCIENCES, INC.
- Classification
- Public company
- Incorporated in
- Delaware
- SEC CIK
- 0000914475
- LEI
- 549300FECER0XBN49756
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $2.9B | $478.6M | $4.6B | $713.0M | $782.7M | |
| FY2024USD | $2.4B | $341.3M | $3.7B | $233.0M | $595.4M | |
| FY2023USD | $1.9B | $249.7M | $3.3B | $251.1M | $389.9M | |
| FY2022USD | $1.5B | $154.5M | $2.4B | $262.9M | $339.4M |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Neurocrine Biosciences in Altss
Track this company’s investors, transactions and relationships in Altss.